Table 3.
DNAm surrogates composing the DNAmCVD score
| Study | DNAm surrogate biomarker | DNAmCVDscore coefficient | Original biomarker/risk factor |
|---|---|---|---|
| This study | DNAmGlucose | 0.0329 | Blood glucose |
| This study | DNAmHDL | − 0.4473 | Blood HDL cholesterol |
| This study | DNAmSBP | 0.1420 | Systolic blood pressure |
| This study | DNAmCRP | 0.0276 | Blood C-reactive protein |
| This study | DNAmPAI1 | 0.1679 | Blood Plasminogen activator inhibitor 1 |
| Gadd et al. 2022 | DNAmSKR3 | 0.0362 | Blood Serine/threonine-protein kinase receptor R3 |
| Gadd et al. 2022 | DNAmHGF | 0.0371 | Blood Hepatocyte growth factor |
| Colicino et al. 2021 | DNAmLeadPatella | 0.0402 | Lead levels in Patella’s bone |
| Lu et al. 2019 | DNAmGDF15 | 0.0947 | Blood Growth Differentiation Factor 15 |
| Lu et al. 2019 | DNAmPACKYRS | 0.1192 | Smoking pack-years |
DNAmCVDscore is computed as a linear combination of standardised (mean = 0, variance = 1) DNAm surrogates with weights listed in the coefficient column. All biomarkers but DNAmHDL have positive coefficients (higher CVD risk associated with a higher value for the biomarker)